To see this page, please, enable javaScript and styleSheets on your browser: Tools -> Internet Options ...
Reload !
Gene TOMM40TABLE OF CONTENTS / OPEN CLOSE ALL PARAGRAPHS
Summary back to top
Compact gene diagram back to top
536 supporting clones for gene TOMM40 back to top
cDNA accession
Links to the sequence
Tissue

most 5' clones
in red
Match
mRNA
From bp
to bp
in mRNA
From bp
to bp
in accs.
Clone encodes
complete protein
(with AA variation)
Features Anomalies
detected by
AceView
Accession
match over
(% length)
Base differences
relative to genome
(% identity)
BP265648 thyroid .a 1 to 580 1 to 580   tiling clone,   580/580
(100 %)
1 diff
(99.9 %id)
NM_001128916.1   .a 1 to 1699 1 to 1699 exact RefSeq, AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 1699/1699
(100 %)
0 diff
(100 %id)
DR006898 Spleen .a 10 to 718 1 to 709       709/709
(100 %)
4 diff
(99.5 %id)
BG707997 brain, hypothalamus .a 12 to 748 1 to 742       742/907
(81 %)
24 diff
(97.4 %id)
BU844914 ovary, teratocarcinoma, cell line .a 18 to 578 12 to 573       562/1066
(52 %)
13 diff
(98.8 %id)
BU931012 ovary, teratocarcinoma, cell line .a 20 to 641 1 to 622       622/978
(63 %)
4 diff
(99.6 %id)
BX452852 neuroblastoma .a 22 to 870 1 to 840       840/843
(99 %)
13 diff
(98.5 %id)
AL519472 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .a 22 to 852 1 to 829   fully sequenced,   829/829
(100 %)
13 diff
(98.5 %id)
BX391338 Placenta Cot 25-normalized .a 22 to 944 1 to 913       913/926
(98 %)
9 diff
(99.1 %id)
BX398295 Placenta Cot 25-normalized .a 22 to 881 1 to 852       852/930
(91 %)
6 diff
(99.4 %id)
BU521141 leiomyosarcoma, uterus .a 22 to 342 5 to 327       323/327
(98 %)
6 diff
(98.2 %id)
CR599747 neuroblastoma .a 23 to 1646 1 to 1624       1624/1624
(100 %)
0 diff
(100 %id)
CR600311 fetal brain .a 23 to 1677 1 to 1655       1655/1655
(100 %)
0 diff
(100 %id)
AL538949 brain, fetal brain .a 23 to 901 1 to 875   fully sequenced,   875/875
(100 %)
8 diff
(99.1 %id)
BI918886 brain .a 23 to 796 1 to 798       793/798
(99 %)
36 diff
(95.5 %id)
TI_57241942   .a 23 to 796 1 to 798       793/798
(99 %)
36 diff
(95.5 %id)
TI_57197781   .a 24 to 641 30 to 648       619/654
(94 %)
8 diff
(98.8 %id)
BI828174 brain, medulla .a 27 to 214 1 to 189       189/189
(100 %)
1 diff
(99.5 %id)
TI_57171562   .a 27 to 821 35 to 836       802/836
(95 %)
14 diff
(98.4 %id)
BI820470 pooled brain, lung, testis .a 28 to 214 1 to 187       187/187
(100 %)
0 diff
(100 %id)
BM453887 melanotic melanoma, skin .a 30 to 742 1 to 717       717/829
(86 %)
11 diff
(98.7 %id)
CR601010 B cells (Ramos cell line) Cot 25-normalized .a 32 to 1665 1 to 1634       1634/1634
(100 %)
0 diff
(100 %id)
BX402046   .a 32 to 901 1 to 867   fully sequenced,   867/867
(100 %)
10 diff
(98.9 %id)
BX443926 fetal liver, Liver .a 38 to 947 1 to 908       908/908
(100 %)
15 diff
(98.4 %id)
BI518650 leukocyte .a 38 to 214 1 to 177       177/177
(100 %)
0 diff
(100 %id)
TI_57201308   .a 38 to 802 111 to 883       773/883
(87 %)
15 diff
(98.4 %id)
TI_44459778   .a 38 to 874 87 to 929       843/993
(84 %)
22 diff
(97.8 %id)
BM818849 stomach .a 38 to 602 1 to 566       566/572
(98 %)
5 diff
(99.2 %id)
BM818851 stomach .a 38 to 519 1 to 482       482/482
(100 %)
1 diff
(99.8 %id)
BM818869 stomach .a 38 to 620 1 to 581       581/581
(100 %)
4 diff
(99.4 %id)
BM818883 stomach .a 38 to 620 1 to 581       581/581
(100 %)
2 diff
(99.7 %id)
BM818888 stomach .a 38 to 615 1 to 576       576/576
(100 %)
2 diff
(99.7 %id)
BM848736 stomach .a 38 to 591 1 to 554       554/554
(100 %)
1 diff
(99.9 %id)
BM849931 stomach .a 38 to 620 1 to 581       581/581
(100 %)
2 diff
(99.7 %id)
BI824124 pooled brain, lung, testis .a 39 to 214 1 to 179       179/179
(100 %)
3 diff
(98.4 %id)
BM819742 stomach .a 39 to 630 1 to 590       590/590
(100 %)
4 diff
(99.4 %id)
CN408012 embryonic stem cells, cell lines H1, H7, andH9 .a 40 to 601 1 to 562       562/562
(100 %)
3 diff
(99.5 %id)
BM923587 pooled colon, kidney, stomach .a 40 to 706 1 to 669       669/1423
(47 %)
5 diff
(99.7 %id)
CR597932 B cells (Ramos cell line) Cot 25-normalized .a 41 to 1667 1 to 1627       1627/1627
(100 %)
0 diff
(100 %id)
AL561126 B cells from Burkitt lymphoma .a 41 to 901 1 to 856   fully sequenced,   856/856
(100 %)
3 diff
(99.7 %id)
BM451205 eye, retinoblastoma .a 41 to 573 1 to 533       533/976
(54 %)
9 diff
(99.1 %id)
CR991951 T-Lymphocytes .a 42 to 640 1 to 600       600/602
(99 %)
6 diff
(99.1 %id)
DB474076 hippocampus .a 44 to 546 1 to 503       503/503
(100 %)
0 diff
(100 %id)
BU171168 eye, retinoblastoma .a 44 to 751 27 to 743       717/974
(73 %)
33 diff
(96.7 %id)
AL541051 placenta .a 45 to 863 1 to 822       822/829
(99 %)
22 diff
(97.4 %id)
BG760541 melanotic melanoma, high MDR (cell line), skin .a 45 to 816 1 to 772       772/772
(100 %)
3 diff
(99.7 %id)
BG761861 melanotic melanoma, high MDR (cell line), skin .a 45 to 729 1 to 686       686/686
(100 %)
3 diff
(99.6 %id)
BM559885 amelanotic melanoma, cell line, skin .a 45 to 682 1 to 639       639/1141
(56 %)
10 diff
(99.2 %id)
CR981394 T-Lymphocytes .a 45 to 659 8 to 622       615/625
(98 %)
8 diff
(98.8 %id)
BQ277689 ovary, teratocarcinoma, cell line .a 47 to 757 1 to 715       715/1085
(65 %)
21 diff
(98.1 %id)
BI830410 brain, medulla .a 48 to 214 1 to 167       167/167
(100 %)
5 diff
(97.1 %id)
BM543915 ovary (pool of 3) .a 48 to 946 1 to 908       908/1110
(81 %)
20 diff
(98.2 %id)
TI_57171406   .a 48 to 835 31 to 817       787/817
(96 %)
14 diff
(98.3 %id)
BM820533 stomach .a 48 to 617 1 to 568       568/568
(100 %)
2 diff
(99.7 %id)
BM819702 stomach .a 48 to 615 1 to 566       566/566
(100 %)
2 diff
(99.7 %id)
BG437045 large cell carcinoma, lung .a 49 to 736 1 to 703       703/1027
(68 %)
35 diff
(96.6 %id)
BC012134 Lung, large cell carcinoma .a 50 to 1662 1 to 1613   tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (15/17 A in genome downstream of last aligned base) 1613/1613
(100 %)
0 diff
(100 %id)
BF204268 muscle, rhabdomyosarcoma .a 50 to 748 1 to 703       703/1064
(66 %)
21 diff
(98.1 %id)
BF309259 muscle, rhabdomyosarcoma .a 50 to 738 1 to 688       669/688
(97 %)
40 diff
(94.2 %id)
BE299424 muscle, rhabdomyosarcoma .a 51 to 741 12 to 701       690/721
(95 %)
22 diff
(97.0 %id)
AL559560 T cells from T cell leukemia .a 52 to 828 1 to 776       776/776
(100 %)
9 diff
(98.9 %id)
BI822881 pooled brain, lung, testis .a 52 to 211 1 to 160       160/160
(100 %)
3 diff
(98.2 %id)
BQ686367 ductal carcinoma, cell line, Pancreas .a 52 to 832 1 to 785       785/912
(86 %)
14 diff
(98.5 %id)
TI_57202078   .a 52 to 864 33 to 852       820/976
(84 %)
26 diff
(97.4 %id)
CR593878 Neuroblastoma Cot 10-normalized .a 53 to 1692 1 to 1640       1640/1640
(100 %)
0 diff
(100 %id)
CR621607 Neuroblastoma Cot 50-normalized .a 53 to 1695 1 to 1643       1643/1643
(100 %)
0 diff
(100 %id)
AL521235 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .a 53 to 899 1 to 843   fully sequenced,   843/843
(100 %)
6 diff
(99.3 %id)
AL528918 brain, neuroblastoma cells, Neuroblastoma Cot 50-normalized .a 53 to 858 1 to 802       802/802
(100 %)
5 diff
(99.4 %id)
BM457248 embryonal carcinoma, cell line, testis .a 54 to 828 1 to 780       780/1026
(76 %)
18 diff
(98.3 %id)
TI_59395896   .a 55 to 741 62 to 745       684/684
(100 %)
7 diff
(99.0 %id)
CR602236 Neuroblastoma Cot 25-normalized .a 56 to 1677 1 to 1622       1622/1622
(100 %)
0 diff
(100 %id)
AL527125 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .a 56 to 964 1 to 904       904/982
(92 %)
18 diff
(98.2 %id)
DB479406 hippocampus .a 56 to 526 1 to 471       471/471
(100 %)
2 diff
(99.6 %id)
BE736461 adenocarcinoma, Pancreas .a 56 to 748 1 to 695       695/1068
(65 %)
10 diff
(99.1 %id)
BM006767 ductal carcinoma, cell line, Pancreas .a 56 to 741 1 to 683       683/683
(100 %)
7 diff
(99.0 %id)
BM847372 lymph node, stomach .a 56 to 181 1 to 125       125/125
(100 %)
1 diff
(99.2 %id)
BM851336 lymph node, stomach .a 56 to 423 1 to 368       368/368
(100 %)
2 diff
(99.5 %id)
BX425451 neuroblastoma .a 57 to 950 1 to 890       890/890
(100 %)
11 diff
(98.8 %id)
BI259843 cervical carcinoma cell line, cervix .a 57 to 748 1 to 741       701/763
(91 %)
86 diff
(88.8 %id)
CR614435 Neuroblastoma Cot 25-normalized .a 58 to 1710 1 to 1653       1653/1653
(100 %)
0 diff
(100 %id)
BQ688247 ductal carcinoma, cell line, Pancreas .a 58 to 945 1 to 896       896/946
(94 %)
11 diff
(98.9 %id)
BQ686683 ductal carcinoma, cell line, Pancreas .a 58 to 863 1 to 813       813/969
(83 %)
12 diff
(98.8 %id)
BM909007 astrocytoma grade IV, cell line, brain .a 59 to 748 1 to 690       690/1124
(61 %)
11 diff
(99.1 %id)
BM924657 pooled colon, kidney, stomach .a 59 to 964 1 to 906       907/1127
(80 %)
22 diff
(98.1 %id)
BM917875 blood, natural killer cells, cell line .a 60 to 540 1 to 482       482/1361
(35 %)
18 diff
(98.7 %id)
BQ953190 epidermoid carcinoma, cell line, lung .a 60 to 448 1 to 389       389/1206
(32 %)
3 diff
(99.8 %id)
BF974937 B-cells, primary B-cells from tonsils (cell line) .a 61 to 862 1 to 797       797/1023
(77 %)
25 diff
(97.6 %id)
BG251414 adenocarcinoma, cell line, Liver .a 61 to 846 1 to 788       788/827
(95 %)
20 diff
(97.6 %id)
BG397732 B-cells, primary B-cells from tonsils (cell line) .a 61 to 838 1 to 775       775/775
(100 %)
11 diff
(98.6 %id)
BG759353 B-cells, primary B-cells from tonsils (cell line) .a 61 to 945 1 to 885       885/885
(100 %)
19 diff
(97.9 %id)
BG756437 B-cells, primary B-cells from tonsils (cell line) .a 61 to 837 1 to 778       778/779
(99 %)
8 diff
(99.0 %id)
BI195835 brain, neuroblastoma .a 61 to 665 1 to 605       605/605
(100 %)
4 diff
(99.4 %id)
BM543911 ovary (pool of 3) .a 61 to 874 7 to 828       822/1146
(71 %)
21 diff
(98.2 %id)
BG104794 adrenal cortex carcinoma, cell line, adrenal gland .a 62 to 748 1 to 697       697/785
(88 %)
30 diff
(96.2 %id)
BG334422 melanotic melanoma, skin .a 62 to 681 1 to 624       624/764
(81 %)
23 diff
(97.0 %id)
BG575348 breast, mammary adenocarcinoma, cell line .a 62 to 748 1 to 708       708/779
(90 %)
39 diff
(95.0 %id)
CT002202 T-Lymphocytes .a 62 to 493 1 to 437       437/437
(100 %)
9 diff
(98.0 %id)
CT002937 T-Lymphocytes .a 62 to 604 1 to 543       543/543
(100 %)
1 diff
(99.9 %id)
BF797780 lymph, lymphoma, cell line .a 63 to 665 1 to 604       604/872
(69 %)
4 diff
(99.6 %id)
BQ899047 brain, neuroblastoma, cell line .a 63 to 944 1 to 889       889/904
(98 %)
11 diff
(98.8 %id)
BU856261 ovary, teratocarcinoma, cell line .a 63 to 742 1 to 688       688/957
(71 %)
16 diff
(98.4 %id)
CT002575 T-Lymphocytes .a 63 to 389 1 to 328       328/328
(100 %)
3 diff
(99.1 %id)
BM559825 amelanotic melanoma, cell line, skin .a 64 to 870 1 to 812       812/1108
(73 %)
18 diff
(98.4 %id)
BM811198 amelanotic melanoma, cell line, skin .a 65 to 746 1 to 684       684/1037
(65 %)
16 diff
(98.5 %id)
BM810921 amelanotic melanoma, cell line, skin .a 65 to 639 1 to 577       577/1247
(46 %)
12 diff
(99.1 %id)
BM913482 amelanotic melanoma, cell line, skin .a 65 to 485 1 to 424       424/1162
(36 %)
5 diff
(99.6 %id)
BM916338 amelanotic melanoma, cell line, skin .a 65 to 1131 1 to 1093       1055/1096
(96 %)
23 diff
(98.0 %id)
BE302953 melanotic melanoma, skin .a 66 to 691 1 to 626       626/627
(99 %)
8 diff
(98.8 %id)
BM541287 leiomyosarcoma, uterus .a 66 to 840 87 to 872       784/1213
(64 %)
24 diff
(98.1 %id)
CX753786 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .a 67 to 745 24 to 697     Submitted on the opposite strand 674/787
(85 %)
10 diff
(98.8 %id)
BC006413 Uterus, endometrium adenocarcinoma .a 69 to 1664 1 to 1597   available from MGC, AAA Possibly primed on the genome, locally A rich (14/15 A in genome downstream of last aligned base) 1597/1597
(100 %)
2 diff
(99.9 %id)
CR593526 Neuroblastoma Cot 25-normalized .a 70 to 1672 1 to 1603       1603/1603
(100 %)
0 diff
(100 %id)
CR596919 Neuroblastoma Cot 25-normalized .a 70 to 1666 1 to 1597       1597/1597
(100 %)
0 diff
(100 %id)
AL526515 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .a 70 to 901 1 to 830   fully sequenced,   830/830
(100 %)
4 diff
(99.6 %id)
BX376167 Neuroblastoma Cot 25-normalized .a 70 to 1203 1 to 1114       1114/1119
(99 %)
26 diff
(97.7 %id)
BE795095 lung, small cell carcinoma .a 70 to 851 1 to 787       787/1162
(67 %)
40 diff
(96.6 %id)
BE390372 endometrium, adenocarcinoma cell line, uterus .a 71 to 748 1 to 688       688/782
(87 %)
24 diff
(97.0 %id)
BM561648 blood, natural killer cells, cell line .a 71 to 870 1 to 801       801/1040
(77 %)
8 diff
(99.3 %id)
BU931193 ovary, teratocarcinoma, cell line .a 71 to 900 1 to 832       832/841
(98 %)
3 diff
(99.7 %id)
BU931659 ovary, teratocarcinoma, cell line .a 71 to 811 1 to 756       753/968
(77 %)
26 diff
(97.4 %id)
BG340804 B-cells, primary B-cells from tonsils (cell line) .a 73 to 806 1 to 743       743/962
(77 %)
24 diff
(97.6 %id)
CT002356 T-Lymphocytes .a 73 to 737 1 to 665       665/668
(99 %)
1 diff
(99.9 %id)
BE378302 endometrium, adenocarcinoma cell line, uterus .a 75 to 519 1 to 444       444/497
(89 %)
7 diff
(98.6 %id)
BG469125 adenocarcinoma cell line, colon .a 78 to 761 1 to 688       688/691
(99 %)
13 diff
(98.2 %id)
BM543922 ovary (pool of 3) .a 79 to 836 1 to 771       767/1124
(68 %)
27 diff
(97.6 %id)
CR978707 T-Lymphocytes .a 79 to 824 1 to 747       747/748
(99 %)
7 diff
(99.1 %id)
CN408017 embryonic stem cells, DMSO-treated H9 cellline .a 82 to 383 1 to 302       302/302
(100 %)
0 diff
(100 %id)
BE394122 endometrium, adenocarcinoma cell line, uterus .a 82 to 706 1 to 624       624/624
(100 %)
3 diff
(99.6 %id)
CN408015 embryonic stem cells, cell lines H1, H7, andH9 .a 85 to 239 1 to 155       155/155
(100 %)
0 diff
(100 %id)
CN408010 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 86 to 322 1 to 237       237/237
(100 %)
0 diff
(100 %id)
BQ230619 brain .a 89 to 950 1 to 868       868/893
(97 %)
18 diff
(98.0 %id)
AF316402   .a 95 to 1656 1 to 1563       1563/1563
(100 %)
1 diff
(100.0 %id)
CR624986 fetal liver .a 96 to 1704 1 to 1609       1609/1609
(100 %)
0 diff
(100 %id)
CR609207 Placenta Cot 25-normalized .a 98 to 1646 1 to 1549       1549/1549
(100 %)
0 diff
(100 %id)
AL551133 placenta, Placenta Cot 25-normalized .a 98 to 924 1 to 825   fully sequenced,   825/825
(100 %)
4 diff
(99.6 %id)
TI_1948243569   .a 104 to 570 132 to 598   fully sequenced,   467/598
(78 %)
6 diff
(99.0 %id)
TI_1948243729   .a 104 to 570 129 to 595   fully sequenced,   467/595
(78 %)
6 diff
(99.0 %id)
TI_1948243889   .a 104 to 570 134 to 600   fully sequenced,   467/600
(77 %)
6 diff
(99.0 %id)
CR593837 T cells (Jurkat cell line) Cot10-normalized .a 109 to 1688 1 to 1580       1580/1580
(100 %)
0 diff
(100 %id)
BX362237   .a 109 to 1083 1 to 973       973/973
(100 %)
6 diff
(99.4 %id)
BI858840 breast, mammary adenocarcinoma, cell line .a 204 to 1106 1 to 918       918/919
(99 %)
30 diff
(96.8 %id)
CR616352 B cells (Ramos cell line) Cot 25-normalized .a 205 to 1679 1 to 1475       1475/1475
(100 %)
0 diff
(100 %id)
BX388189   .a 205 to 978 1 to 774   fully sequenced,   774/774
(100 %)
0 diff
(100 %id)
BQ883428 brain, neuroblastoma, cell line .a 227 to 1093 1 to 867       867/872
(99 %)
5 diff
(99.5 %id)
AF316401   .a 244 to 1503 1 to 1261       1261/1261
(100 %)
3 diff
(99.8 %id)
CX163890 human embryonic stem cells differentiated toan early endodermal cell type .a 265 to 1083 1 to 819       819/819
(100 %)
2 diff
(99.8 %id)
BG768177 melanotic melanoma, high MDR (cell line), skin .a 267 to 1126 8 to 869       862/870
(99 %)
26 diff
(97.1 %id)
BG283881 adenocarcinoma, cell line, Prostate .a 285 to 1111 1 to 824       824/839
(98 %)
19 diff
(97.8 %id)
TI_154177673   .a 318 to 1176 78 to 936       859/859
(100 %)
16 diff
(98.2 %id)
TI_154177752   .a 318 to 1187 77 to 952       876/876
(100 %)
18 diff
(98.0 %id)
BU553348 ovary, teratocarcinoma, cell line .a 351 to 1229 1 to 890       890/890
(100 %)
19 diff
(97.9 %id)
CD108318 brain, Pituitary .a 366 to 1204 1 to 843       843/844
(99 %)
5 diff
(99.5 %id)
BG287001 bladder, transitional cell papilloma, cell line .a 367 to 1138 1 to 772       772/817
(94 %)
19 diff
(97.7 %id)
BU957583 adenocarcinoma, cell line, breast .a 368 to 1167 1 to 803       803/927
(86 %)
11 diff
(98.9 %id)
BX409520 brain, fetal brain .a 384 to 1247 852 to 1     Submitted on the opposite strand 852/852
(100 %)
31 diff
(96.4 %id)
BQ923214 epidermoid carcinoma, cell line, lung .a 401 to 1309 1 to 927       927/962
(96 %)
36 diff
(96.3 %id)
AF316398   .a 405 to 1077 1 to 673       673/673
(100 %)
3 diff
(99.6 %id)
BG107700 Bone, osteosarcoma, cell line .a 405 to 1115 1 to 727       725/728
(99 %)
19 diff
(97.4 %id)
BE274894 melanotic melanoma, skin .a 407 to 1145 1 to 735       735/795
(92 %)
14 diff
(98.3 %id)
BE728222 melanotic melanoma, skin .a 407 to 1207 1 to 795       795/1055
(75 %)
22 diff
(98.0 %id)
BG180520 adenocarcinoma, cell line, Prostate .a 407 to 1206 1 to 791       791/909
(87 %)
31 diff
(96.6 %id)
BF314434 brain, neuroblastoma .a 408 to 1155 1 to 748       748/1022
(73 %)
31 diff
(97.0 %id)
CV810619 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .a 408 to 1141 1 to 734       734/734
(100 %)
1 diff
(99.9 %id)
BE408217 choriocarcinoma, placenta .a 424 to 1129 1 to 700       700/700
(100 %)
11 diff
(98.5 %id)
BE208555 lung, small cell carcinoma .a 428 to 1073 1 to 646       646/646
(100 %)
3 diff
(99.6 %id)
AF316399   .a 436 to 1699 1 to 1262   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 1262/1263
(99 %)
27 diff
(97.9 %id)
BM790169 stomach .a 438 to 1081 1 to 641       641/641
(100 %)
5 diff
(99.3 %id)
BM790053 stomach .a 438 to 1075 1 to 637       637/637
(100 %)
4 diff
(99.4 %id)
TI_1948243570   .a 509 to 1189 803 to 123   fully sequenced,   681/803
(84 %)
0 diff
(100 %id)
TI_1948243730   .a 509 to 1189 805 to 125   fully sequenced,   681/805
(84 %)
0 diff
(100 %id)
TI_1948243890   .a 509 to 1189 804 to 124   fully sequenced,   681/804
(84 %)
0 diff
(100 %id)
BF348194 anaplastic oligodendroglioma with 1p/19qloss, brain .a 636 to 1270 1 to 632       632/1018
(62 %)
18 diff
(98.3 %id)
BF793576 adrenal cortex carcinoma, cell line, adrenal gland .a 641 to 1238 1 to 595       595/959
(62 %)
11 diff
(98.9 %id)
BQ649980 hepatocellular carcinoma, cell line, Liver .a 641 to 1483 22 to 873       852/907
(93 %)
28 diff
(97.0 %id)
BG396265 eye, retinoblastoma .a 644 to 1144 1 to 502       502/502
(100 %)
2 diff
(99.7 %id)
CK903445 Islets of Langerhans, Pancreas .a 644 to 1244 1 to 601       601/601
(100 %)
5 diff
(99.2 %id)
BI964827 Islets of Langerhans, Pancreas .a 661 to 1187 1 to 527       527/527
(100 %)
0 diff
(100 %id)
CR604933 Neuroblastoma Cot 25-normalized .a 666 to 1707 1 to 1042       1042/1042
(100 %)
0 diff
(100 %id)
BX333315 Neuroblastoma Cot 25-normalized .a 666 to 1707 1 to 1032       1032/1032
(100 %)
23 diff
(97.8 %id)
BE393966 endometrium, adenocarcinoma cell line, uterus .a 671 to 1250 1 to 578       578/578
(100 %)
2 diff
(99.7 %id)
BM008804 adenocarcinoma, Pancreas .a 671 to 1202 1 to 532       532/532
(100 %)
0 diff
(100 %id)
TI_59386518   .a 671 to 1202 61 to 592       532/532
(100 %)
0 diff
(100 %id)
BX101036 melanocyte .a 676 to 1304 1 to 629       629/638
(98 %)
3 diff
(99.6 %id)
AL527109 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .a 700 to 1677 977 to 1       977/1035
(94 %)
20 diff
(98.1 %id)
BX361776   .a 700 to 1636 925 to 1       925/970
(95 %)
25 diff
(97.5 %id)
BM791403 stomach .a 704 to 1230 1 to 527       527/527
(100 %)
0 diff
(100 %id)
BX347810 Neuroblastoma Cot 50-normalized .a 709 to 1645 1 to 931       931/934
(99 %)
22 diff
(97.7 %id)
BP420495 small intestine .a 712 to 1235 1 to 525     Submitted on the opposite strand 525/525
(100 %)
5 diff
(99.1 %id)
BU191200 melanotic melanoma, cell line, skin .a 714 to 1614 17 to 919       903/953
(94 %)
60 diff
(93.8 %id)
BU160980 melanotic melanoma, cell line, skin .a 715 to 1448 1 to 737       737/934
(78 %)
6 diff
(99.4 %id)
BQ680995 melanotic melanoma, cell line, skin .a 715 to 1545 1 to 847       847/943
(89 %)
38 diff
(96.0 %id)
BQ678543 melanotic melanoma, cell line, skin .a 715 to 1482 1 to 781       781/894
(87 %)
19 diff
(97.9 %id)
BI196232 brain, neuroblastoma .a 724 to 1337 1 to 611       611/611
(100 %)
5 diff
(99.2 %id)
CN408014 embryonic stem cells, cell lines H1, H7, andH9 .a 732 to 1347 1 to 618       618/618
(100 %)
4 diff
(99.4 %id)
BE260140 brain, neuroblastoma .a 744 to 1327 1 to 584       584/584
(100 %)
8 diff
(98.7 %id)
BX328807   .a 745 to 1688 947 to 1       947/947
(100 %)
7 diff
(99.3 %id)
BX432761 B cells (Ramos cell line) .a 748 to 1696 964 to 1       964/985
(97 %)
40 diff
(96.0 %id)
AL580432 T cells from T cell leukemia .a 748 to 1671 920 to 1       920/920
(100 %)
28 diff
(97.0 %id)
BX389242 Neuroblastoma Cot 25-normalized .a 754 to 1261 1 to 506       506/548
(92 %)
26 diff
(95.3 %id)
BX452851 neuroblastoma .a 764 to 1646 883 to 1       883/883
(100 %)
5 diff
(99.5 %id)
TI_149312559   .a 765 to 1686 983 to 66       918/1070
(85 %)
16 diff
(98.6 %id)
TI_227712533   .a 767 to 1708 1021 to 86   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 936/1030
(90 %)
20 diff
(98.1 %id)
BX451313 fetal liver, Liver .a 773 to 1682 1 to 910       910/932
(97 %)
25 diff
(97.4 %id)
BX451312 fetal liver, Liver .a 777 to 1650 1 to 872       868/872
(99 %)
29 diff
(96.7 %id)
BQ951559 epidermoid carcinoma, cell line, lung .a 800 to 1552 1 to 758       758/857
(88 %)
8 diff
(99.1 %id)
BF528514 anaplastic oligodendroglioma with 1p/19qloss, brain .a 807 to 1249 1 to 450       450/452
(99 %)
7 diff
(98.5 %id)
BU153543 epithelioid carcinoma, Pancreas .a 810 to 1608 1 to 815   AAA   815/896
(90 %)
21 diff
(97.7 %id)
BX326832 Neuroblastoma Cot 50-normalized .a 817 to 1678 1 to 863   AAA   863/882
(97 %)
22 diff
(97.6 %id)
AL561783 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .a 822 to 1657 841 to 1   fully sequenced,   841/841
(100 %)
24 diff
(97.2 %id)
BX451323 fetal liver, Liver .a 825 to 1704 1 to 875       875/875
(100 %)
25 diff
(97.2 %id)
BX333631 Neuroblastoma Cot 25-normalized .a 834 to 1672 837 to 1       837/837
(100 %)
4 diff
(99.6 %id)
BX376166 Neuroblastoma Cot 25-normalized .a 839 to 1672 838 to 1       769/838
(91 %)
22 diff
(97.4 %id)
AL521234 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .a 840 to 1689 852 to 4   fully sequenced,   849/852
(99 %)
1 diff
(99.9 %id)
AL562695 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .a 840 to 1666 821 to 1   fully sequenced,   821/821
(100 %)
7 diff
(99.2 %id)
AL567578 brain, fetal brain .a 840 to 1677 838 to 1   fully sequenced,   838/838
(100 %)
4 diff
(99.6 %id)
AL582408 B cells from Burkitt lymphoma .a 840 to 1667 830 to 1   fully sequenced,   830/830
(100 %)
4 diff
(99.6 %id)
BX402045   .a 840 to 1665 823 to 1   fully sequenced,   823/823
(100 %)
5 diff
(99.4 %id)
AL528917 brain, neuroblastoma cells, Neuroblastoma Cot 50-normalized .a 846 to 1695 848 to 1       848/848
(100 %)
19 diff
(97.8 %id)
CN408008 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 848 to 1280 1 to 433       433/433
(100 %)
0 diff
(100 %id)
BQ948196 epidermoid carcinoma, cell line, lung .a 868 to 1677 43 to 863       821/957
(85 %)
41 diff
(95.8 %id)
BM556816 duodenal adenocarcinoma, cell line, small intestine .a 869 to 1626 1 to 768       768/935
(82 %)
16 diff
(98.3 %id)
TI_149294927   .a 871 to 1709 921 to 84   AAA   838/970
(86 %)
16 diff
(98.4 %id)
BX451324 fetal liver, Liver .a 874 to 1700 51 to 875       825/875
(94 %)
25 diff
(97.2 %id)
AL531647 brain, fetal liver, Liver, neuroblastoma cells .a 881 to 1639 787 to 28       760/787
(96 %)
6 diff
(99.3 %id)
BX389335   .a 884 to 1289 1 to 406       406/406
(100 %)
31 diff
(92.4 %id)
BU558220 adenocarcinoma, cell line, breast .a 884 to 1680 12 to 815       804/921
(87 %)
26 diff
(97.2 %id)
BU944082 adenocarcinoma, cell line, breast .a 884 to 1699 17 to 831   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 815/831
(98 %)
9 diff
(99.0 %id)
BU944652 adenocarcinoma, cell line, breast .a 889 to 1704 24 to 844       821/971
(84 %)
27 diff
(97.3 %id)
BU539186 adenocarcinoma, cell line, breast .a 893 to 1610 1 to 725       725/1033
(70 %)
25 diff
(97.6 %id)
AL551090 placenta, Placenta Cot 25-normalized .a 894 to 1646 753 to 1   fully sequenced,   753/753
(100 %)
2 diff
(99.8 %id)
BF830401 leiomios .a 905 to 1180 278 to 6     Submitted on the opposite strand 273/280
(97 %)
0 diff
(100 %id)
BF351232 head_neck .a 907 to 1246 351 to 10       342/351
(97 %)
7 diff
(98.1 %id)
BX439943 brain, fetal brain .a 907 to 1682 777 to 1       777/777
(100 %)
45 diff
(94.3 %id)
BX439944 brain, fetal brain .a 907 to 1671 763 to 1       763/763
(100 %)
8 diff
(99.0 %id)
BX439945 brain, fetal brain .a 907 to 1699 1 to 790   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 790/790
(100 %)
12 diff
(98.5 %id)
BX439946 brain, fetal brain .a 907 to 1707 1 to 800       800/802
(99 %)
7 diff
(99.2 %id)
BX388188   .a 917 to 1677 764 to 4   fully sequenced,   761/764
(99 %)
1 diff
(99.9 %id)
BF826012 head_normal .a 930 to 1270 1 to 341       341/341
(100 %)
1 diff
(99.8 %id)
BM978121 lung .a 930 to 1664 751 to 17   AAA Possibly primed on the genome, locally A rich (14/15 A in genome downstream of last aligned base) 735/735
(100 %)
3 diff
(99.6 %id)
BQ212715 melanotic melanoma, skin .a 962 to 1677 1 to 722       722/904
(79 %)
25 diff
(97.3 %id)
CD367061 Alveolar Macrophage, lung .a 976 to 1708 745 to 10       736/745
(98 %)
3 diff
(99.6 %id)
BX376365 Neuroblastoma Cot 25-normalized .a 989 to 1653 692 to 27   AAA   666/923
(72 %)
6 diff
(99.4 %id)
AA325119 brain, cerebellum .a 992 to 1200 1 to 209       209/209
(100 %)
1 diff
(99.6 %id)
BM458957 melanotic melanoma, skin .a 1017 to 1699 1 to 684   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 684/684
(100 %)
1 diff
(99.9 %id)
TI_149277376   .a 1026 to 1709 770 to 88   AAA   683/683
(100 %)
11 diff
(98.4 %id)
AL568708 placenta .a 1263 to 1679 415 to 2       414/593
(69 %)
0 diff
(100 %id)
NM_006114.2   .b 1 to 1696 1 to 1696 exact RefSeq, AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 1696/1696
(100 %)
0 diff
(100 %id)
BG032362 breast, mammary adenocarcinoma, cell line .b 17 to 745 1 to 724   tiling clone,   724/904
(80 %)
8 diff
(99.2 %id)
AF043250   .b 18 to 1696 1 to 1680   tiling clone, AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 1680/1680
(100 %)
1 diff
(100.0 %id)
CR593671 B cells (Ramos cell line) .b 21 to 1693 1 to 1673   tiling clone,   1673/1673
(100 %)
0 diff
(100 %id)
BG281399 melanotic melanoma, skin .b 36 to 715 1 to 657       631/657
(96 %)
31 diff
(95.3 %id)
BG334713 melanotic melanoma, skin .b 36 to 819 1 to 801       737/879
(83 %)
52 diff
(94.1 %id)
CB991968 placenta, pre-eclamptic placenta .b 36 to 741 28 to 739       712/824
(86 %)
22 diff
(97.4 %id)
CB996425 placenta, pre-eclamptic placenta .b 36 to 722 28 to 711       684/764
(89 %)
20 diff
(97.4 %id)
CR599342 B cells (Ramos cell line) .b 42 to 1679 1 to 1638       1638/1638
(100 %)
0 diff
(100 %id)
AL560119 B cells (Ramos cell line), B cells from Burkitt lymphoma .b 42 to 898 1 to 855   fully sequenced,   855/855
(100 %)
4 diff
(99.6 %id)
BM451748 eye, retinoblastoma .b 43 to 943 1 to 915       911/1075
(84 %)
20 diff
(98.2 %id)
BX432762 B cells (Ramos cell line) .b 45 to 947 29 to 940       912/950
(96 %)
29 diff
(97.0 %id)
BX432763 B cells (Ramos cell line) .b 45 to 535 29 to 524       496/752
(65 %)
15 diff
(98.1 %id)
BX442941 B cells (Ramos cell line) .b 45 to 1043 29 to 1018       990/1024
(96 %)
31 diff
(97.0 %id)
BQ945067 carcinoma, cell line, Prostate .b 47 to 719 1 to 680       680/985
(69 %)
9 diff
(99.1 %id)
BE407307 choriocarcinoma, placenta .b 55 to 511 1 to 460       460/525
(87 %)
8 diff
(98.5 %id)
CR598474 Neuroblastoma Cot 10-normalized .b 58 to 1663 1 to 1606       1606/1606
(100 %)
0 diff
(100 %id)
AL519995 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .b 58 to 898 1 to 843   fully sequenced,   843/843
(100 %)
15 diff
(98.3 %id)
BI521430 pooled pancreas and spleen .b 60 to 211 1 to 147       147/147
(100 %)
8 diff
(94.6 %id)
BF204556 muscle, rhabdomyosarcoma .b 62 to 745 1 to 682       682/816
(83 %)
11 diff
(98.7 %id)
CN408007 embryonic stem cells, cell lines H1, H7, andH9 .b 63 to 518 8 to 462       455/462
(98 %)
7 diff
(98.5 %id)
BE871511 adenocarcinoma, colon .b 63 to 745 1 to 705       705/827
(85 %)
43 diff
(94.9 %id)
BU173295 eye, retinoblastoma .b 64 to 748 1 to 691       691/986
(70 %)
20 diff
(98.0 %id)
DR761675 embryonic stem .b 66 to 883 1 to 818       818/818
(100 %)
2 diff
(99.8 %id)
BG336167 choriocarcinoma, placenta .b 67 to 873 1 to 794       794/1050
(75 %)
60 diff
(94.3 %id)
BE907017 epithelioid carcinoma, Pancreas .b 69 to 673 1 to 605       605/605
(100 %)
3 diff
(99.6 %id)
CR622462 Neuroblastoma Cot 10-normalized .b 73 to 1686 1 to 1614       1614/1614
(100 %)
0 diff
(100 %id)
AL519816 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .b 73 to 898 1 to 824   fully sequenced,   824/824
(100 %)
5 diff
(99.4 %id)
BE882034 leiomyosarcoma, uterus .b 78 to 859 1 to 782       782/850
(92 %)
20 diff
(97.7 %id)
CR982674 T-Lymphocytes .b 80 to 799 1 to 721       721/728
(99 %)
8 diff
(99.0 %id)
BE794312 lung, small cell carcinoma .b 83 to 745 1 to 663       663/671
(98 %)
3 diff
(99.6 %id)
AL519994 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .b 837 to 1636 823 to 26   fully sequenced,   798/823
(96 %)
3 diff
(99.7 %id)
AL561823 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .b 837 to 1686 850 to 1   fully sequenced,   850/850
(100 %)
3 diff
(99.7 %id)
AL560118 B cells (Ramos cell line), B cells from Burkitt lymphoma .b 837 to 1675 847 to 4   fully sequenced,   844/847
(99 %)
1 diff
(99.9 %id)
NM_001128917.1   .c 1 to 1791 1 to 1791 exact RefSeq, AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 1791/1791
(100 %)
0 diff
(100 %id)
BM562598 duodenal adenocarcinoma, cell line, small intestine .c 20 to 939 5 to 935   tiling clone,   931/1063
(87 %)
32 diff
(97.0 %id)
BM742960 Ascites, stomach .c 36 to 530 1 to 496       496/496
(100 %)
1 diff
(99.8 %id)
BM742183 Ascites, stomach .c 36 to 606 1 to 569       569/569
(100 %)
4 diff
(99.3 %id)
BM743717 Ascites, stomach .c 36 to 595 1 to 560       560/560
(100 %)
1 diff
(99.9 %id)
BM757224 Ascites, stomach .c 36 to 617 1 to 582       582/582
(100 %)
1 diff
(99.9 %id)
BM764945 Ascites, stomach .c 36 to 602 1 to 567       567/567
(100 %)
1 diff
(99.9 %id)
BM773232 Ascites, stomach .c 36 to 384 1 to 349       349/349
(100 %)
0 diff
(100 %id)
BM781633 Ascites, stomach .c 36 to 618 1 to 583       583/583
(100 %)
1 diff
(99.9 %id)
CR618807 HeLa cells Cot 25-normalized .c 41 to 1741 1 to 1701 exact     1701/1701
(100 %)
0 diff
(100 %id)
AL556080 placenta .c 41 to 993 1 to 948   fully sequenced,   948/948
(100 %)
16 diff
(98.4 %id)
ES313114 beard hair, skin .c 46 to 145 1 to 99       99/99
(100 %)
3 diff
(97.0 %id)
BG470987 eye, retinoblastoma .c 49 to 818 1 to 776       776/777
(99 %)
14 diff
(98.2 %id)
BC001779 Eye, retinoblastoma .c 50 to 1754 1 to 1706 exact tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (15/17 A in genome downstream of last aligned base) 1706/1706
(100 %)
1 diff
(100.0 %id)
BQ673928 epidermoid carcinoma, cell line, salivary gland .c 54 to 732 1 to 678       678/922
(73 %)
8 diff
(99.2 %id)
BQ673297 epidermoid carcinoma, cell line, salivary gland .c 54 to 819 1 to 768       768/969
(79 %)
18 diff
(98.2 %id)
BM042451 melanotic melanoma, cell line, skin .c 61 to 733 1 to 673       673/676
(99 %)
3 diff
(99.6 %id)
BM042302 melanotic melanoma, cell line, skin .c 61 to 632 1 to 572       572/582
(98 %)
6 diff
(99.0 %id)
BE254129 eye, retinoblastoma .c 69 to 728 1 to 659       659/659
(100 %)
4 diff
(99.4 %id)
BQ061471 lymph, lymphoma, cell line .c 71 to 924 1 to 862       862/1092
(78 %)
16 diff
(98.6 %id)
BQ212477 melanotic melanoma, skin .c 74 to 819 1 to 751       751/930
(80 %)
14 diff
(98.5 %id)
BM742229 Ascites, stomach .c 75 to 534 1 to 458       458/459
(99 %)
3 diff
(99.4 %id)
CR594218 T cells (Jurkat cell line) Cot10-normalized .c 90 to 1763 1 to 1674 exact     1674/1674
(100 %)
0 diff
(100 %id)
AL558662 T cells from T cell leukemia .c 90 to 1038 1 to 947       947/947
(100 %)
19 diff
(98.0 %id)
BM763272 myeloma .c 95 to 761 1 to 667       667/667
(100 %)
0 diff
(100 %id)
BM763278 myeloma .c 95 to 763 1 to 669       669/669
(100 %)
0 diff
(100 %id)
BM853321 myeloma .c 95 to 508 1 to 414       414/414
(100 %)
1 diff
(99.8 %id)
BM851670 myeloma .c 95 to 459 1 to 365       365/365
(100 %)
7 diff
(98.1 %id)
BM849182 myeloma .c 95 to 712 1 to 618       618/618
(100 %)
0 diff
(100 %id)
BM798832 myeloma .c 95 to 320 1 to 226       226/226
(100 %)
0 diff
(100 %id)
BG481496 choriocarcinoma, placenta .c 97 to 858 1 to 764       764/764
(100 %)
3 diff
(99.7 %id)
BG765072 melanotic melanoma, high MDR (cell line), skin .c 97 to 963 1 to 875       875/934
(93 %)
22 diff
(97.7 %id)
BC017224 Skin, melanotic melanoma, high MDR. .c 98 to 1791 1 to 1694 exact available from MGC, AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 1694/1694
(100 %)
1 diff
(100.0 %id)
BQ216750 large cell carcinoma, lung .c 102 to 814 12 to 732       721/886
(81 %)
25 diff
(97.2 %id)
CT002047 T-Lymphocytes .c 103 to 587 1 to 487       487/487
(100 %)
4 diff
(99.2 %id)
BM687262 eye, optic nerve .c 103 to 575 9 to 481     Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 473/481
(98 %)
8 diff
(98.4 %id)
CR597944 Neuroblastoma Cot 25-normalized .c 104 to 1761 1 to 1658 exact     1658/1658
(100 %)
0 diff
(100 %id)
CR599210 Neuroblastoma Cot 25-normalized .c 104 to 1764 1 to 1661 exact tiling clone,   1661/1661
(100 %)
0 diff
(100 %id)
AL523270 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .c 104 to 962 1 to 858   fully sequenced,   858/858
(100 %)
7 diff
(99.2 %id)
BX333632 Neuroblastoma Cot 25-normalized .c 104 to 893 1 to 787       787/787
(100 %)
4 diff
(99.5 %id)
BE612759 adenocarcinoma, ovary .c 104 to 738 1 to 640       640/727
(88 %)
18 diff
(97.6 %id)
CR623716 B cells (Ramos cell line) .c 107 to 1740 1 to 1634 exact     1634/1634
(100 %)
0 diff
(100 %id)
BX404929 B cells (Ramos cell line) .c 107 to 1001 1 to 891   fully sequenced,   891/891
(100 %)
7 diff
(99.3 %id)
BG743980 blood, natural killer cells, cell line .c 113 to 892 1 to 777   fully sequenced,   777/777
(100 %)
12 diff
(98.5 %id)
BE733018 choriocarcinoma, placenta .c 119 to 923 1 to 796       796/975
(81 %)
19 diff
(98.1 %id)
BE901896 choriocarcinoma, placenta .c 119 to 969 1 to 847       847/867
(97 %)
31 diff
(96.5 %id)
BG339350 leiomyosarcoma cell line, uterus .c 181 to 732 41 to 598       558/1108
(50 %)
18 diff
(98.4 %id)
BX447110 neuroblastoma .c 182 to 1034 67 to 914       848/914
(92 %)
9 diff
(99.1 %id)
CN408013 embryonic stem cells, cell lines H1, H7, andH9 .c 182 to 634 5 to 457       453/457
(99 %)
7 diff
(98.5 %id)
BM810167 amelanotic melanoma, cell line, skin .c 182 to 838 35 to 693       659/1210
(54 %)
16 diff
(98.7 %id)
TI_57152908   .c 182 to 849 50 to 745       696/868
(80 %)
48 diff
(94.5 %id)
BE792826 lung, small cell carcinoma .c 184 to 737 1 to 554       554/554
(100 %)
5 diff
(99.1 %id)
AL531648 brain, fetal liver, Liver, neuroblastoma cells .c 188 to 1132 1 to 943       943/951
(99 %)
25 diff
(97.4 %id)
BE255207 eye, retinoblastoma .c 191 to 817 9 to 635       627/636
(98 %)
9 diff
(98.6 %id)
BE894748 melanotic melanoma, skin .c 191 to 843 14 to 670       657/1002
(65 %)
19 diff
(98.2 %id)
BI824819 pooled brain, lung, testis .c 192 to 306 1 to 114       114/114
(100 %)
1 diff
(99.2 %id)
TI_57196915   .c 192 to 840 50 to 703       654/877
(74 %)
28 diff
(96.9 %id)
CX760502 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .c 194 to 839 1 to 643     Submitted on the opposite strand 643/734
(87 %)
16 diff
(97.9 %id)
EL733200 mixed .c 197 to 808 1 to 612       612/612
(100 %)
0 diff
(100 %id)
BX328808   .c 201 to 1144 1 to 937       937/937
(100 %)
11 diff
(98.9 %id)
CX755548 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .c 204 to 925 39 to 750     Submitted on the opposite strand 712/787
(90 %)
21 diff
(97.4 %id)
BX376650 Neuroblastoma Cot 50-normalized .c 205 to 1144 1 to 947       947/1023
(92 %)
19 diff
(98.2 %id)
BG831434 epithelioid carcinoma cell line, Pancreas .c 207 to 1144 1 to 933       933/974
(95 %)
32 diff
(96.8 %id)
AW238848 lung, cell line .c 234 to 666 1 to 433       433/433
(100 %)
2 diff
(99.6 %id)
CX865916 embryonic stem .c 236 to 988 1 to 753     Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 753/753
(100 %)
2 diff
(99.8 %id)
BX368404 Neuroblastoma Cot 25-normalized .c 250 to 1084 841 to 1       841/919
(91 %)
44 diff
(95.3 %id)
TI_57191246   .c 293 to 1198 52 to 972       887/922
(96 %)
25 diff
(97.3 %id)
BX326599 Neuroblastoma Cot 50-normalized .c 306 to 1127 818 to 1       818/931
(87 %)
12 diff
(98.8 %id)
BX368400 Neuroblastoma Cot 25-normalized .c 313 to 1087 782 to 1       782/819
(95 %)
58 diff
(93.0 %id)
BX347588 Neuroblastoma Cot 25-normalized .c 314 to 1090 777 to 1       777/898
(86 %)
11 diff
(98.8 %id)
BX347585 Neuroblastoma Cot 25-normalized .c 316 to 1052 736 to 1       736/736
(100 %)
31 diff
(95.8 %id)
TI_1948243408   .c 316 to 1281 1101 to 125       926/1301
(71 %)
57 diff
(95.7 %id)
BG682741 brain, neuroblastoma, cell line .c 317 to 1143 1 to 831       831/903
(92 %)
12 diff
(98.7 %id)
BU191501 ductal carcinoma, cell line, Pancreas .c 335 to 1030 26 to 727       702/1072
(65 %)
24 diff
(97.8 %id)
CA495270   .c 348 to 1141 26 to 823       798/915
(87 %)
18 diff
(98.1 %id)
CR985307 T-Lymphocytes .c 349 to 1042 1 to 695       695/711
(97 %)
3 diff
(99.6 %id)
CX760303 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .c 358 to 1098 1 to 732     Submitted on the opposite strand 732/737
(99 %)
14 diff
(98.2 %id)
BQ220035 epithelioid carcinoma, Pancreas .c 363 to 1047 1 to 685       685/929
(73 %)
7 diff
(99.3 %id)
BI160239 epithelioid carcinoma cell line, Pancreas .c 386 to 1038 1 to 654       654/654
(100 %)
6 diff
(99.1 %id)
BI161016 epithelioid carcinoma cell line, Pancreas .c 386 to 1142 1 to 762       762/762
(100 %)
13 diff
(98.3 %id)
CF145451 CNCAP(3)T-225 cell line, Prostate .c 403 to 1063 1 to 663       663/663
(100 %)
8 diff
(98.8 %id)
CF145517 CNCAP(3)T-225 cell line, Prostate .c 403 to 1063 1 to 664       664/664
(100 %)
9 diff
(98.7 %id)
BG471573 eye, retinoblastoma .c 441 to 1105 1 to 663       663/664
(99 %)
14 diff
(97.9 %id)
BU944829 adenocarcinoma, cell line, breast .c 460 to 1101 1 to 638       638/717
(88 %)
5 diff
(99.4 %id)
BX368499   .c 473 to 1115 643 to 1       643/668
(96 %)
18 diff
(97.4 %id)
BE073404 breast .c 491 to 636 1 to 146       146/146
(100 %)
0 diff
(100 %id)
BU171837 melanotic melanoma, skin .c 491 to 1143 38 to 696       659/875
(75 %)
22 diff
(97.5 %id)
BE266819 lung, small cell carcinoma .c 492 to 1034 1 to 543       543/543
(100 %)
3 diff
(99.5 %id)
BE389507 endometrium, adenocarcinoma cell line, uterus .c 498 to 1102 1 to 607       607/612
(99 %)
7 diff
(98.9 %id)
BE389153 endometrium, adenocarcinoma cell line, uterus .c 499 to 1144 1 to 645       645/720
(89 %)
3 diff
(99.6 %id)
BE259731 brain, neuroblastoma .c 502 to 1059 1 to 559       559/560
(99 %)
4 diff
(99.3 %id)
BM791820 stomach .c 517 to 1051 1 to 535       535/535
(100 %)
0 diff
(100 %id)
BQ221318 embryonal carcinoma, cell line, testis .c 525 to 1136 1 to 618       618/913
(67 %)
12 diff
(98.7 %id)
BE272522 Kidney, renal cell adenocarcinoma .c 531 to 1125 1 to 592       592/598
(98 %)
5 diff
(99.2 %id)
BX451061 fetal liver, Liver .c 533 to 1339 805 to 1       805/869
(92 %)
11 diff
(98.8 %id)
BX453693 fetal liver, Liver .c 533 to 1338 804 to 1       804/957
(84 %)
16 diff
(98.4 %id)
BM555600 amelanotic melanoma, cell line, skin .c 533 to 1401 34 to 908       875/1003
(87 %)
17 diff
(98.4 %id)
CN408018 embryonic stem cells, cell lines H1, H7, andH9 .c 550 to 1139 1 to 590       590/590
(100 %)
0 diff
(100 %id)
BU500412   .c 560 to 1430 7 to 892       886/939
(94 %)
32 diff
(96.6 %id)
BU179406 melanotic melanoma, cell line, skin .c 586 to 1312 1 to 735       735/830
(88 %)
12 diff
(98.6 %id)
BM808578 amelanotic melanoma, cell line, skin .c 590 to 1401 133 to 962       830/1073
(77 %)
31 diff
(97.2 %id)
BM423707 amelanotic melanoma, cell line, skin .c 590 to 1264 134 to 828       695/1061
(65 %)
31 diff
(97.1 %id)
BM770473 stomach .c 593 to 1173 7 to 585       581/585
(99 %)
12 diff
(98.0 %id)
BM766156 stomach .c 598 to 858 1 to 261       261/261
(100 %)
1 diff
(99.7 %id)
BM766065 stomach .c 598 to 1063 1 to 466       466/466
(100 %)
1 diff
(99.8 %id)
BM771762 stomach .c 598 to 1201 1 to 603       603/603
(100 %)
3 diff
(99.6 %id)
CN408011 embryonic stem cells, DMSO-treated H9 cellline .c 602 to 1173 1 to 572       572/572
(100 %)
1 diff
(99.9 %id)
CU452586 epidermis .c 603 to 1139 12 to 548       537/554
(96 %)
11 diff
(98.1 %id)
CX788577 human embryonic stem cells .c 603 to 1361 1 to 759       759/759
(100 %)
1 diff
(99.9 %id)
BQ651428 hepatocellular carcinoma, cell line, Liver .c 606 to 1468 1 to 874       874/914
(95 %)
19 diff
(98.0 %id)
BQ651474 hepatocellular carcinoma, cell line, Liver .c 606 to 1357 1 to 761       761/912
(83 %)
12 diff
(98.7 %id)
BM745852 stomach .c 607 to 1062 1 to 456       456/456
(100 %)
6 diff
(98.7 %id)
CX784058 human embryonic stem cells .c 608 to 1071 1 to 464       464/464
(100 %)
0 diff
(100 %id)
CX753509 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .c 614 to 1349 1 to 728     Submitted on the opposite strand 728/799
(91 %)
16 diff
(98.0 %id)
CN408009 embryonic stem cells, cell lines H1, H7, andH9 .c 620 to 1255 20 to 655       636/655
(97 %)
6 diff
(99.1 %id)
BG696556 skin .c 624 to 1239 9 to 626       618/630
(98 %)
7 diff
(98.9 %id)
CU454064 epidermis .c 627 to 1139 21 to 533       513/537
(95 %)
10 diff
(98.2 %id)
BE397847 Burkitt lymphoma, lymph .c 627 to 1239 19 to 632       614/632
(97 %)
6 diff
(99.1 %id)
BE792085 lung, small cell carcinoma .c 630 to 1354 1 to 725       725/913
(79 %)
14 diff
(98.5 %id)
BE397283 Burkitt lymphoma, lymph .c 636 to 1240 1 to 605       605/605
(100 %)
0 diff
(100 %id)
BF981354 duodenal adenocarcinoma, cell line, small intestine .c 639 to 1296 1 to 656       656/665
(98 %)
5 diff
(99.3 %id)
BG392670 embryonal carcinoma, cell line, testis .c 655 to 1296 1 to 641       641/670
(95 %)
4 diff
(99.5 %id)
BE531289 adenocarcinoma, Pancreas .c 660 to 1330 1 to 672       672/1020
(65 %)
8 diff
(99.3 %id)
BF685091 leiomyosarcoma cell line, uterus .c 661 to 1328 1 to 665       665/875
(76 %)
18 diff
(98.0 %id)
BF917641 uterus_tumor .c 681 to 858 178 to 1     Submitted on the opposite strand 178/178
(100 %)
2 diff
(98.9 %id)
BU147301 melanotic melanoma, cell line, skin .c 683 to 1572 1 to 904       904/935
(96 %)
23 diff
(97.6 %id)
BG821266 adenocarcinoma cell line, colon .c 685 to 1358 1 to 683       683/686
(99 %)
25 diff
(96.4 %id)
BU854785 ovary, teratocarcinoma, cell line .c 700 to 1545 1 to 861       861/949
(90 %)
20 diff
(97.9 %id)
BF237791 leiomyosarcoma cell line, uterus .c 716 to 1334 1 to 616       616/621
(99 %)
5 diff
(99.2 %id)
BQ883468 brain, neuroblastoma, cell line .c 722 to 1590 1 to 874       874/892
(97 %)
14 diff
(98.5 %id)
BE294208 muscle, rhabdomyosarcoma .c 724 to 1331 1 to 605       605/615
(98 %)
10 diff
(98.4 %id)
BE294415 muscle, rhabdomyosarcoma .c 724 to 1340 1 to 613       613/613
(100 %)
5 diff
(99.2 %id)
CB594951 Blood, promyelocytic leukemia .c 726 to 1569 1 to 856       856/873
(98 %)
21 diff
(97.6 %id)
BX348068   .c 747 to 1052 1 to 307       307/307
(100 %)
1 diff
(99.7 %id)
CN408016 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .c 765 to 1076 1 to 313       313/313
(100 %)
3 diff
(99.1 %id)
AW375548 colon .c 768 to 1023 275 to 20       256/275
(93 %)
2 diff
(99.3 %id)
BX348103   .c 775 to 1052 1 to 278       278/278
(100 %)
0 diff
(100 %id)
BX348104   .c 776 to 1021 1 to 244       244/282
(86 %)
5 diff
(98.3 %id)
BG744659 blood, natural killer cells, cell line .c 862 to 1751 894 to 4   fully sequenced,   891/894
(99 %)
19 diff
(97.9 %id)
BI519739 leukocyte .c 892 to 1720 880 to 19       788/881
(89 %)
18 diff
(98.0 %id)
TI_44459780   .c 892 to 1720 880 to 19       788/881
(89 %)
18 diff
(98.0 %id)
AL562183 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .c 932 to 1761 823 to 1   fully sequenced,   823/823
(100 %)
12 diff
(98.6 %id)
AL578433 placenta .c 932 to 1741 813 to 1   fully sequenced,   813/813
(100 %)
12 diff
(98.6 %id)
BX404928 B cells (Ramos cell line) .c 971 to 1740 771 to 1   fully sequenced,   771/771
(100 %)
18 diff
(97.7 %id)
BG683406 brain, neuroblastoma, cell line .c 1141 to 1736 621 to 17       605/902
(67 %)
0 diff
(100 %id)
CX865860 embryonic stem .c 1327 to 1791 491 to 27   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 465/465
(100 %)
1 diff
(99.8 %id)
BU727611 eye, optic nerve .c 1389 to 1791 422 to 19   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 404/404
(100 %)
4 diff
(99.1 %id)
BC047528 testis .d 1 to 3409 1 to 3409 exact tiling clone, available from MGC, AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 3409/3409
(100 %)
27 diff
(99.3 %id)
BM476360 duodenal adenocarcinoma, cell line, small intestine .d 2136 to 3019 1 to 884   tiling clone,   884/1102
(80 %)
12 diff
(99.0 %id)
CN414692 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .d 2174 to 2563 1 to 390       390/390
(100 %)
0 diff
(100 %id)
BF592181 breast, lobullar carcinoma in situ .d 2327 to 2581 29 to 283     Submitted on the opposite strand 255/320
(79 %)
1 diff
(99.7 %id)
BM083326 brain, glioblastoma (pooled) .d 2754 to 3404 651 to 1       651/657
(99 %)
31 diff
(95.3 %id)
BE390364 endometrium, adenocarcinoma cell line, uterus .d 2757 to 3388 1 to 634       634/656
(96 %)
11 diff
(98.4 %id)
BQ181995 Knee, Osteoarthritic Cartilage .d 2759 to 3419 679 to 19   AAA   661/665
(99 %)
2 diff
(99.7 %id)
TI_149290502   .d 2767 to 3419 781 to 137   AAA   645/900
(71 %)
32 diff
(96.5 %id)
TI_149286359   .d 2779 to 3419 718 to 81   AAA   638/1171
(54 %)
34 diff
(97.1 %id)
CA421937 Bone, Enchondroma cell line .d 2791 to 3419 647 to 19   AAA   629/629
(100 %)
2 diff
(99.7 %id)
CA424171 cell lines, Chondrosarcoma .d 2792 to 3409 638 to 19   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 620/620
(100 %)
3 diff
(99.6 %id)
BX328513 Neuroblastoma Cot 25-normalized .d 2800 to 3238 1 to 429       429/440
(97 %)
23 diff
(94.8 %id)
CK903444 Islets of Langerhans, Pancreas .d 2817 to 3399 587 to 5       583/587
(99 %)
0 diff
(100 %id)
EC486216 Prostate .d 2829 to 2942 114 to 1       114/114
(100 %)
0 diff
(100 %id)
BU677549 lung .d 2830 to 3419 609 to 19   AAA   591/591
(100 %)
2 diff
(99.7 %id)
EC579563 Prostate .d 2831 to 2942 111 to 2       110/111
(99 %)
0 diff
(100 %id)
CR616015 B cells (Ramos cell line) Cot 25-normalized .d 2839 to 3417 1 to 579   tiling clone,   579/579
(100 %)
0 diff
(100 %id)
AL582950 B cells from Burkitt lymphoma .d 2839 to 3417 1 to 578       578/578
(100 %)
3 diff
(99.5 %id)
TI_149289136   .d 2840 to 3395 621 to 70       552/731
(75 %)
0 diff
(100 %id)
CD671593 eye, Iris .d 2857 to 3409 1 to 554   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 554/554
(100 %)
1 diff
(99.9 %id)
BU558304 adenocarcinoma, cell line, breast .d 2893 to 3419 1 to 527       527/552
(95 %)
2 diff
(99.7 %id)
BQ019777 Chondrosarcoma, Left Pubic Bone .d 2899 to 3419 539 to 19   AAA   521/521
(100 %)
2 diff
(99.7 %id)
CA422508 cell lines, Chondrosarcoma .d 2910 to 3419 528 to 19   AAA   510/510
(100 %)
0 diff
(100 %id)
BQ228853 embryonal carcinoma, cell line, testis .d 2911 to 3417 1 to 507       507/526
(96 %)
3 diff
(99.5 %id)
DB542875 hippocampus .d 2918 to 3409 1 to 493     Submitted on the opposite strand 493/493
(100 %)
1 diff
(99.8 %id)
BM971959 lung .d 2931 to 3419 507 to 19   AAA   489/489
(100 %)
4 diff
(99.2 %id)
DB548106 hippocampus .d 2934 to 3409 1 to 477     Submitted on the opposite strand 477/477
(100 %)
1 diff
(99.8 %id)
BM917504 blood, natural killer cells, cell line .d 2935 to 3409 518 to 44   AAA Submitted on the opposite strand 475/1384
(34 %)
9 diff
(99.4 %id)
DB571998 hypothalamus .d 2940 to 3409 1 to 470     Submitted on the opposite strand 470/470
(100 %)
4 diff
(99.2 %id)
BM449489 leiomyosarcoma, uterus .d 2941 to 3409 13 to 482   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 470/482
(97 %)
6 diff
(98.8 %id)
BM970733 lung .d 2945 to 3388 446 to 1       446/446
(100 %)
5 diff
(98.9 %id)
AI761505 colon, colon tumor, RER+ .d 2946 to 3417 476 to 4       473/476
(99 %)
0 diff
(100 %id)
BG236014 blood, lymphocyte .d 2947 to 3418 473 to 1       473/473
(100 %)
4 diff
(99.2 %id)
AW167805 serous papillary carcinoma, high grade, 2pooled tumors, uterus .d 2948 to 3374 428 to 1       428/428
(100 %)
2 diff
(99.6 %id)
AI984024 adenocarcinoma, Pancreas .d 2951 to 3372 423 to 1       423/423
(100 %)
6 diff
(98.6 %id)
BE505009 pooled germ cell tumors .d 2952 to 3411 461 to 2       460/489
(94 %)
0 diff
(100 %id)
BF196819 brain, glioblastoma (pooled) .d 2952 to 3409 461 to 1       461/461
(100 %)
3 diff
(99.4 %id)
AW170188 cervix .d 2978 to 3417 441 to 1       441/441
(100 %)
3 diff
(99.4 %id)
BM928595 hepatocellular carcinoma, cell line, Liver .d 2982 to 3419 476 to 36   AAA Submitted on the opposite strand 441/1074
(41 %)
2 diff
(99.9 %id)
AI363425 anaplastic oligodendroglioma, brain .d 2983 to 3420 443 to 4       440/445
(98 %)
0 diff
(100 %id)
AI401557 anaplastic oligodendroglioma, brain .d 2983 to 3409 428 to 1       428/430
(99 %)
1 diff
(99.8 %id)
BX372810 Neuroblastoma Cot 25-normalized .d 2985 to 3412 426 to 1       426/426
(100 %)
5 diff
(98.9 %id)
TI_154103704   .d 2985 to 3419 514 to 79   AAA   436/856
(50 %)
1 diff
(99.9 %id)
AW662237 2 pooled high-grade transitional celltumors, genitourinary tract .d 2987 to 3353 367 to 1       367/367
(100 %)
1 diff
(99.8 %id)
BE673249 Prostate .d 2988 to 3420 433 to 1       433/433
(100 %)
2 diff
(99.6 %id)
BM985155 lung .d 2988 to 3419 451 to 19   AAA   433/434
(99 %)
3 diff
(99.4 %id)
AI569515 serous papillary carcinoma, high grade, 2pooled tumors, uterus .d 2991 to 3408 418 to 1       418/418
(100 %)
3 diff
(99.3 %id)
BX391409   .d 2994 to 3393 436 to 36   AAA Possibly primed on the genome, locally A rich (15/17 A in genome downstream of last aligned base) 401/405
(99 %)
12 diff
(97.1 %id)
AI304353 adenocarcinoma, colon .d 2994 to 3409 418 to 1       418/422
(99 %)
2 diff
(99.6 %id)
AI887476 serous papillary carcinoma, high grade, 2pooled tumors, uterus .d 2996 to 3399 418 to 15       404/418
(96 %)
0 diff
(100 %id)
AW301127 colon, moderately differentiated adenocarcinoma .d 2996 to 3399 408 to 5       404/408
(99 %)
0 diff
(100 %id)
AI751735 Bone, Hip .d 2996 to 3409 423 to 9       415/423
(98 %)
0 diff
(100 %id)
AI187199   .d 2998 to 3378 381 to 1       381/381
(100 %)
5 diff
(98.7 %id)
CA313325 Human Lung Epithelial cells, lung .d 2998 to 3419 441 to 19   AAA   423/423
(100 %)
1 diff
(99.8 %id)
AA993403   .d 3003 to 3419 433 to 18   AAA   416/416
(100 %)
9 diff
(97.9 %id)
BU681743 lung .d 3005 to 3409 423 to 19   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 405/405
(100 %)
13 diff
(96.8 %id)
AL581154 T cells from T cell leukemia .d 3006 to 3346 392 to 51       342/398
(85 %)
0 diff
(100 %id)
AA587364 colon, colon tumor RER+ .d 3008 to 3419 410 to 1       410/410
(100 %)
9 diff
(97.9 %id)
BQ448628 Knee, Osteoarthritic Cartilage .d 3009 to 3409 419 to 19   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 401/401
(100 %)
0 diff
(100 %id)
AA586613 germ cell tumor .d 3011 to 3420 409 to 1       409/409
(100 %)
6 diff
(98.6 %id)
AW071435 connective tissue, five pooled sarcomas, including myxoidliposarcoma, solitary fibrous tumor, malignant fibroushistiocytoma, gastrointestinal stromal tumor, andmesothelioma .d 3011 to 3419 410 to 1       410/410
(100 %)
2 diff
(99.6 %id)
CA445920 Chondrosarcoma, Left Pelvis .d 3011 to 3420 417 to 8       410/417
(98 %)
0 diff
(100 %id)
BU629548 cell lines, Chondrosarcoma .d 3011 to 3392 382 to 1       382/382
(100 %)
10 diff
(97.4 %id)
AI147294 brain, glioblastoma (pooled) .d 3013 to 3415 403 to 1       403/407
(99 %)
0 diff
(100 %id)
AI799632 poorly differentiated adenocarcinoma withsignet ring cell features, stomach .d 3013 to 3409 425 to 29   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 397/402
(98 %)
10 diff
(97.6 %id)
BE046056 follicular carcinoma, thyroid .d 3013 to 3420 408 to 1       408/416
(98 %)
2 diff
(99.6 %id)
CD369979 Alveolar Macrophage, lung .d 3013 to 3418 415 to 10       406/418
(97 %)
0 diff
(100 %id)
BU521814 leiomyosarcoma, uterus .d 3016 to 3388 1 to 373       373/374
(99 %)
3 diff
(99.2 %id)
BF346146 anaplastic oligodendroglioma with 1p/19qloss, brain .d 3017 to 3419 1 to 403   AAA   403/403
(100 %)
0 diff
(100 %id)
TI_59392831   .d 3017 to 3417 49 to 448       400/694
(57 %)
6 diff
(99.2 %id)
CX755589 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .d 3018 to 3409 1 to 392   AAA Submitted on the opposite strand 392/392
(100 %)
0 diff
(100 %id)
BM014773 breast, mammary adenocarcinoma, cell line .d 3019 to 3417 1 to 398       398/419
(94 %)
6 diff
(98.6 %id)
BG056246 brain, glioblastoma with probably TP53 mutation andwithout EGFR amplification .d 3021 to 3412 392 to 1       392/392
(100 %)
0 diff
(100 %id)
BQ010645 placenta .d 3021 to 3419 416 to 18   AAA   399/400
(99 %)
1 diff
(99.8 %id)
AA612638 Prostate, prostate tumor .d 3026 to 3418 392 to 1       392/392
(100 %)
7 diff
(98.3 %id)
BF221714 Prostate .d 3032 to 3420 389 to 1       389/389
(100 %)
1 diff
(99.8 %id)
AI686326 Prostate .d 3033 to 3420 388 to 1       388/388
(100 %)
1 diff
(99.8 %id)
N52152 multiple sclerosis lesions .d 3036 to 3419 383 to 1       383/385
(99 %)
6 diff
(98.5 %id)
AI624180 adenocarcinoma, Pancreas .d 3045 to 3388 394 to 51   AAA   344/350
(98 %)
0 diff
(100 %id)
AI433123 lymph node, lymphoma, follicular mixed small and largecell .d 3050 to 3419 381 to 12   AAA   370/370
(100 %)
3 diff
(99.2 %id)
AI582625 Kidney .d 3050 to 3409 374 to 15   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 360/360
(100 %)
0 diff
(100 %id)
AI016046 Kidney .d 3052 to 3419 368 to 1       368/368
(100 %)
3 diff
(99.2 %id)
AI285023 adenocarcinoma, colon .d 3055 to 3419 377 to 13   AAA   365/365
(100 %)
0 diff
(100 %id)
AA912489 Dorsal root ganglion, peripheral nervous system .d 3059 to 3374 315 to 1       315/315
(100 %)
4 diff
(98.8 %id)
CA418652 Chondrosarcoma Grade II, Left Pelvis .d 3061 to 3409 367 to 19   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 349/357
(97 %)
1 diff
(99.8 %id)
AI268065 carcinoid, lung .d 3063 to 3419 370 to 14   AAA   357/357
(100 %)
1 diff
(99.8 %id)
AI566898 anaplastic oligodendroglioma, brain .d 3064 to 3417 376 to 23       354/376
(94 %)
0 diff
(100 %id)
BQ887598 eye, retinoblastoma .d 3064 to 3419 1 to 356   AAA   356/356
(100 %)
0 diff
(100 %id)
BM685875 eye, Retina Foveal and Macular .d 3074 to 3409 8 to 343   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 336/343
(97 %)
0 diff
(100 %id)
AI341961 pooled germ cell tumors .d 3095 to 3372 278 to 1       278/278
(100 %)
1 diff
(99.7 %id)
AA523645 metastatic prostate bone lesion .d 3100 to 3409 8 to 318   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 311/318
(97 %)
6 diff
(98.2 %id)
TI_149283943   .d 3101 to 3419 401 to 83   AAA   319/702
(45 %)
5 diff
(99.3 %id)
BM984326 lung .d 3101 to 3419 337 to 19   AAA   319/319
(100 %)
5 diff
(98.5 %id)
AI190910   .d 3102 to 3412 311 to 1       311/311
(100 %)
0 diff
(100 %id)
CR616832 Neuroblastoma Cot 25-normalized .d 3112 to 3417 1 to 306       306/306
(100 %)
0 diff
(100 %id)
BX351167 Neuroblastoma Cot 25-normalized .d 3112 to 3406 295 to 1       295/295
(100 %)
4 diff
(98.7 %id)
BX370924 Neuroblastoma Cot 25-normalized .d 3112 to 3417 306 to 1       306/306
(100 %)
4 diff
(98.7 %id)
BX370926 Neuroblastoma Cot 25-normalized .d 3112 to 3417 1 to 306       306/306
(100 %)
2 diff
(99.4 %id)
AA558223 adrenal adenoma, adrenal gland .d 3116 to 3419 322 to 19   AAA   304/304
(100 %)
4 diff
(98.7 %id)
AA652893 normal prostate, Prostate .d 3116 to 3411 295 to 1       295/295
(100 %)
3 diff
(99.0 %id)
AA653296   .d 3117 to 3410 293 to 1       293/293
(100 %)
2 diff
(99.4 %id)
AI970827 Prostate .d 3121 to 3420 305 to 6       300/305
(98 %)
0 diff
(100 %id)
BM471701 melanotic melanoma, skin .d 3128 to 3372 1 to 245   AAA Possibly primed on the genome, locally A rich (15/17 A in genome downstream of last aligned base) 245/245
(100 %)
1 diff
(99.6 %id)
BU160894 melanotic melanoma, skin .d 3134 to 3419 4 to 289   AAA   286/289
(98 %)
6 diff
(98.0 %id)
AA456161 ovarian tumor, ovary .d 3154 to 3410 1 to 255   fully sequenced,   255/255
(100 %)
6 diff
(97.7 %id)
BF114617 pooled .d 3161 to 3419 259 to 1       259/259
(100 %)
0 diff
(100 %id)
AI659668 Prostate .d 3162 to 3410 249 to 1       249/249
(100 %)
0 diff
(100 %id)
AI566838 anaplastic oligodendroglioma, brain .d 3172 to 3374 203 to 1       203/203
(100 %)
0 diff
(100 %id)
BF063004 colon, colon tumor, RER+ .d 3189 to 3418 230 to 1       230/230
(100 %)
2 diff
(99.2 %id)
CR987275 T-Lymphocytes .d 3194 to 3409 1 to 216   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 216/216
(100 %)
0 diff
(100 %id)
BI963177 Islets of Langerhans, Pancreas .d 3197 to 3399 207 to 2       206/207
(99 %)
0 diff
(100 %id)
AI340152 2 pooled tumors (clear cell type), Kidney .d 3200 to 3409 233 to 24   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 210/210
(100 %)
4 diff
(98.1 %id)
AA443094 ovarian tumor, ovary .d 3207 to 3419 212 to 1   fully sequenced,   212/212
(100 %)
2 diff
(99.1 %id)
AI277417 placenta .d 3218 to 3419 219 to 18   AAA   202/202
(100 %)
2 diff
(99.1 %id)
BE858950 Prostate .d 3218 to 3410 193 to 1       193/193
(100 %)
0 diff
(100 %id)
BE787465 large cell carcinoma, lung .d 3223 to 3414 1 to 192       192/192
(100 %)
2 diff
(99.0 %id)
BU601312 mixed (pool of 40 RNAs) .d 3237 to 3418 1 to 182   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 182/182
(100 %)
2 diff
(99.0 %id)
H09599 whole brain .d 3253 to 3409 171 to 15   AAA Possibly primed on the genome, locally A rich (8/8 A in genome downstream of last aligned base) 157/157
(100 %)
0 diff
(100 %id)
AA993726   .d 3254 to 3377 124 to 1       124/124
(100 %)
0 diff
(100 %id)
AI869161 anaplastic oligodendroglioma, brain .d 3279 to 3419 152 to 12   AAA   141/141
(100 %)
0 diff
(100 %id)
EC520723 Prostate .d 3282 to 3411 1 to 126       126/126
(100 %)
5 diff
(96.1 %id)
EC484958 Prostate .d 3295 to 3410 22 to 138       117/138
(84 %)
6 diff
(95.7 %id)
AA877244 colon, colon tumor RER+ .d 3315 to 3406 92 to 1       92/92
(100 %)
0 diff
(100 %id)
GD138710   .d 3344 to 3417 8 to 81       74/86
(86 %)
1 diff
(98.9 %id)
TI_57171610   .e 1 to 924 34 to 951   tiling clone,   919/954
(96 %)
34 diff
(96.5 %id)
TI_59385318   .e 547 to 1196 161 to 813   tiling clone,   653/656
(99 %)
17 diff
(97.5 %id)
TI_154178792   .f 1 to 841 54 to 883 exact tiling clone,   830/885
(93 %)
22 diff
(97.6 %id)
TI_154178808   .f 1 to 871 61 to 915 exact tiling clone,   855/915
(93 %)
32 diff
(96.6 %id)
BG012169 placenta_normal .g-u 1 to 192 205 to 10 V3R T4X L5P G6W N7G ... tiling clone,   196/209
(93 %)
0 diff
(100 %id)
BI010633 lung_normal .g-u 1 to 192 205 to 10 V3R T4X L5P G6W N7G ...     196/209
(93 %)
0 diff
(100 %id)
CR592041 Neuroblastoma Cot 25-normalized Gene TOMM40, variant not shown         Suspected internal deletion, this clone was ignored    
BX376366 Neuroblastoma Cot 25-normalized Gene TOMM40, variant not shown         Suspected internal deletion, this clone was ignored    
? Gene Summary Gene on genome mRNA:.a, .b, .c, .d, .e, .f, .g-u Alternative mRNAs features, proteins, introns, exons, sequences Expression Tissue Function, regulation, related genes DCI